Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

257 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
Roehrborn CG, Siami P, Barkin J, Damião R, Becher E, Miñana B, Mirone V, Castro R, Wilson T, Montorsi F; CombAT Study Group. Roehrborn CG, et al. Eur Urol. 2009 Feb;55(2):461-71. doi: 10.1016/j.eururo.2008.10.037. Epub 2008 Nov 6. Eur Urol. 2009. PMID: 19013011 Clinical Trial.
Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH.
D'Agate S, Wilson T, Adalig B, Manyak M, Palacios-Moreno JM, Chavan C, Oelke M, Roehrborn C, Della Pasqua O. D'Agate S, et al. World J Urol. 2020 Feb;38(2):463-472. doi: 10.1007/s00345-019-02783-x. Epub 2019 May 11. World J Urol. 2020. PMID: 31079189 Free PMC article. Clinical Trial.
Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
Roehrborn CG, Nickel JC, Andriole GL, Gagnier RP, Black L, Wilson TH, Rittmaster RS. Roehrborn CG, et al. Among authors: wilson th. Urology. 2011 Sep;78(3):641-6. doi: 10.1016/j.urology.2011.03.063. Epub 2011 Jul 20. Urology. 2011. PMID: 21764428 Clinical Trial.
Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: long-term results from the combination of dutasteride and tamsulosin study.
Chung BH, Lee SH, Roehrborn CG, Siami PF, Major-Walker K, Wilson TH, Montorsi F; CombAT Study Group. Chung BH, et al. Among authors: wilson th. Int J Urol. 2012 Nov;19(11):1031-5. doi: 10.1111/j.1442-2042.2012.03091.x. Epub 2012 Jul 9. Int J Urol. 2012. PMID: 22774774 Clinical Trial.
Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG, Barkin J, Tubaro A, Emberton M, Wilson TH, Brotherton BJ, Castro R. Roehrborn CG, et al. Among authors: wilson th. BJU Int. 2014 Apr;113(4):623-35. doi: 10.1111/bju.12500. Epub 2014 Jan 9. BJU Int. 2014. PMID: 24127818 Clinical Trial.
257 results